212 related articles for article (PubMed ID: 30216647)
1. Seasonal influenza immunisation: Strategies for older adults.
Schaffner W; van Buynder P; McNeil S; Osterhaus ADME
Int J Clin Pract; 2018 Oct; 72(10):e13249. PubMed ID: 30216647
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
4. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for seasonal and pandemic influenza.
Nichol KL; Treanor JJ
J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
7. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
[TBL] [Abstract][Full Text] [Related]
9. Effective Immunization of Older Adults Against Seasonal Influenza.
Schaffner W; Chen WH; Hopkins RH; Neuzil K
Am J Med; 2018 Aug; 131(8):865-873. PubMed ID: 29544989
[TBL] [Abstract][Full Text] [Related]
10. Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine.
Goldeck D; Theeten H; Hassouneh F; Oettinger L; Wistuba-Hamprecht K; Cools N; Tsitsilonis OE; Pawelec G
Vaccine; 2017 Aug; 35(34):4330-4338. PubMed ID: 28689651
[TBL] [Abstract][Full Text] [Related]
11. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
[TBL] [Abstract][Full Text] [Related]
13. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
Nunzi E; Iorio AM; Camilloni B
Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
[TBL] [Abstract][Full Text] [Related]
14. Seasonal influenza vaccines.
Fiore AE; Bridges CB; Cox NJ
Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
[TBL] [Abstract][Full Text] [Related]
15. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach.
Lambert ND; Ovsyannikova IG; Pankratz VS; Jacobson RM; Poland GA
Expert Rev Vaccines; 2012 Aug; 11(8):985-94. PubMed ID: 23002979
[TBL] [Abstract][Full Text] [Related]
16. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
19. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
